Boehringer Ingelheim
This article was originally published in The Tan Sheet
Executive Summary
German firm is considering divestiture of its Pharmaton Business as part of an ongoing review of its over-the-counter portfolio while weighing "the merits of alternative options," the company announced Sept. 9. The country's top drug maker by sales issued the statement in response to "rumors circulating in the market regarding a potential sale of parts of the Consumer Health Care Business." The segment up for review affects multivitamin and ginseng products sold under the Pharmaton brand, Boehringer said. The option is currently being discussed with financial consultants though no decision has as yet been made, the firm maintains...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.